These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26896685)

  • 1. Influenza B vaccine lineage selection--an optimized trivalent vaccine.
    Mosterín Höpping A; Fonville JM; Russell CA; James S; Smith DJ
    Vaccine; 2016 Mar; 34(13):1617-1622. PubMed ID: 26896685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.
    Rudenko L; Kiseleva I; Krutikova E; Stepanova E; Rekstin A; Donina S; Pisareva M; Grigorieva E; Kryshen K; Muzhikyan A; Makarova M; Sparrow EG; Torelli G; Kieny MP
    PLoS One; 2018; 13(12):e0208028. PubMed ID: 30507951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Quadrivalent influenza vaccine: What is changed and what are the benefits?].
    Mosnier A; Launay O; Martinez L; Gavazzi G; Josset L; Crepey P; Hannoun C; Weil-Olivier C; Gaillat J
    Presse Med; 2018 Oct; 47(10):842-853. PubMed ID: 30219205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine.
    Reed C; Meltzer MI; Finelli L; Fiore A
    Vaccine; 2012 Mar; 30(11):1993-8. PubMed ID: 22226861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the case for trivalent or quadrivalent influenza vaccines.
    Baxter D
    Hum Vaccin Immunother; 2016 Oct; 12(10):2712-2717. PubMed ID: 27435025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine.
    Skowronski DM; Janjua NZ; Sabaiduc S; De Serres G; Winter AL; Gubbay JB; Dickinson JA; Fonseca K; Charest H; Bastien N; Li Y; Kwindt TL; Mahmud SM; Van Caeseele P; Krajden M; Petric M
    J Infect Dis; 2014 Jul; 210(1):126-37. PubMed ID: 24446529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rationale for quadrivalent influenza vaccines.
    Ambrose CS; Levin MJ
    Hum Vaccin Immunother; 2012 Jan; 8(1):81-8. PubMed ID: 22252006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC; Pavia-Ruz N; Cruz-Valdez A; Aranza Doniz C; Chandrasekaran V; Dewé W; Liu A; Innis BL; Jain VK
    Vaccine; 2014 Mar; 32(13):1480-7. PubMed ID: 24486352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-replication BM2SR vaccine provides sterilizing immunity and cross-lineage influenza B virus protection in mice.
    Moser MJ; Hatta Y; Gabaglia C; Sanchez A; Dias P; Sarawar S; Kawaoka Y; Hatta M; Neumann G; Bilsel P
    Vaccine; 2019 Jul; 37(32):4533-4542. PubMed ID: 31280945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.
    Toback SL; Levin MJ; Block SL; Belshe RB; Ambrose CS; Falloon J
    Expert Rev Vaccines; 2012 Nov; 11(11):1293-303. PubMed ID: 23151111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2017-18 Influenza Season.
    Grohskopf LA; Sokolow LZ; Broder KR; Walter EB; Bresee JS; Fry AM; Jernigan DB
    MMWR Recomm Rep; 2017 Aug; 66(2):1-20. PubMed ID: 28841201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivated quadrivalent split-virus seasonal influenza vaccine (Fluarix® quadrivalent): a review of its use in the prevention of disease caused by influenza A and B.
    McKeage K
    Drugs; 2013 Sep; 73(14):1587-94. PubMed ID: 24022123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the vaccine-induced influenza B virus hemagglutinin-specific antibody dependent cellular cytotoxicity response.
    de Vries RD; Nieuwkoop NJ; Krammer F; Hu B; Rimmelzwaan GF
    Virus Res; 2020 Feb; 277():197839. PubMed ID: 31837382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of adjuvant: Trivalent vaccine with quadrivalent-like protection against heterologous Yamagata-lineage influenza B virus.
    Myers ML; Gallagher JR; Woolfork DD; Stradtmann-Carvalho RK; Maldonado-Puga S; Bock KW; Boyoglu-Barnum S; Syeda H; Creanga A; Alves DA; Kanekiyo M; Harris AK
    Front Immunol; 2022; 13():1002286. PubMed ID: 36248851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The need for quadrivalent vaccine against seasonal influenza.
    Belshe RB
    Vaccine; 2010 Sep; 28 Suppl 4():D45-53. PubMed ID: 20713260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022-23 Influenza Season.
    Grohskopf LA; Blanton LH; Ferdinands JM; Chung JR; Broder KR; Talbot HK; Morgan RL; Fry AM
    MMWR Recomm Rep; 2022 Aug; 71(1):1-28. PubMed ID: 36006864
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL; Yi T; Sheldon E; Dubovsky F; Falloon J
    Vaccine; 2011 Nov; 29(50):9391-7. PubMed ID: 21983154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
    Domachowske JB; Pankow-Culot H; Bautista M; Feng Y; Claeys C; Peeters M; Innis BL; Jain V
    J Infect Dis; 2013 Jun; 207(12):1878-87. PubMed ID: 23470848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated Sentinel Surveillance Linking Genetic, Antigenic, and Epidemiologic Monitoring of Influenza Vaccine-Virus Relatedness and Effectiveness During the 2013-2014 Influenza Season.
    Skowronski DM; Chambers C; Sabaiduc S; De Serres G; Winter AL; Dickinson JA; Gubbay J; Fonseca K; Charest H; Krajden M; Petric M; Mahmud SM; Van Caeseele P; Bastien N; Eshaghi A; Li Y
    J Infect Dis; 2015 Sep; 212(5):726-39. PubMed ID: 25784728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccine effectiveness against influenza A(H3N2) and B among laboratory-confirmed, hospitalised older adults, Europe, 2017-18: A season of B lineage mismatched to the trivalent vaccine.
    Rose AMC; Kissling E; Gherasim A; Casado I; Bella A; Launay O; Lazăr M; Marbus S; Kuliese M; Syrjänen R; Machado A; Kurečić Filipović S; Larrauri A; Castilla J; Alfonsi V; Galtier F; Ivanciuc A; Meijer A; Mickiene A; Ikonen N; Gómez V; Lovrić Makarić Z; Moren A; Valenciano M;
    Influenza Other Respir Viruses; 2020 May; 14(3):302-310. PubMed ID: 32022450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.